Ryan Geschwindt

435 total citations
15 papers, 337 citations indexed

About

Ryan Geschwindt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ryan Geschwindt has authored 15 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Ryan Geschwindt's work include Cancer Immunotherapy and Biomarkers (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Ryan Geschwindt is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Ryan Geschwindt collaborates with scholars based in United States, United Kingdom and France. Ryan Geschwindt's co-authors include Niranjan Y. Sardesai, Ingegerd Hellström, Lý Thị Trần, Curtis L. Glover, Harvey I. Pass, Michael Craig Miller, W. Jeffrey Allard, Thorsten Verch, Steven G. DuBois and Andrew D.J. Pearson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ryan Geschwindt

15 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan Geschwindt United States 10 137 94 80 47 37 15 337
Wan Sun United States 10 145 1.1× 51 0.5× 149 1.9× 31 0.7× 39 1.1× 24 322
Kevin Huang United States 8 56 0.4× 91 1.0× 44 0.6× 19 0.4× 44 1.2× 10 226
Sarah Benafif United Kingdom 8 167 1.2× 134 1.4× 131 1.6× 80 1.7× 64 1.7× 23 359
Karan Rai United States 8 116 0.8× 163 1.7× 165 2.1× 48 1.0× 81 2.2× 16 414
Hualei Bu China 11 54 0.4× 173 1.8× 118 1.5× 59 1.3× 91 2.5× 24 354
Siân Morgan United Kingdom 8 64 0.5× 107 1.1× 57 0.7× 117 2.5× 54 1.5× 16 304
Valentina Sini Italy 13 93 0.7× 63 0.7× 242 3.0× 53 1.1× 106 2.9× 25 399
C. K. Park South Korea 8 165 1.2× 87 0.9× 116 1.4× 25 0.5× 44 1.2× 14 400
Nicoletta Provinciali Italy 9 54 0.4× 83 0.9× 175 2.2× 48 1.0× 119 3.2× 22 308

Countries citing papers authored by Ryan Geschwindt

Since Specialization
Citations

This map shows the geographic impact of Ryan Geschwindt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan Geschwindt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan Geschwindt more than expected).

Fields of papers citing papers by Ryan Geschwindt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan Geschwindt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan Geschwindt. The network helps show where Ryan Geschwindt may publish in the future.

Co-authorship network of co-authors of Ryan Geschwindt

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan Geschwindt. A scholar is included among the top collaborators of Ryan Geschwindt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan Geschwindt. Ryan Geschwindt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Luke, Jason J., Marwan Fakih, Charles Schneider, et al.. (2023). Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British Journal of Cancer. 128(12). 2227–2235. 19 indexed citations
2.
Naing, Aung, John D. Powderly, John Nemunaitis, et al.. (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for ImmunoTherapy of Cancer. 10(3). e004223–e004223. 12 indexed citations
3.
Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations
4.
Piha‐Paul, Sarina A., Tara C. Mitchell, Solmaz Sahebjam, et al.. (2020). 419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial. Regular and Young Investigator Award Abstracts. A255–A255. 3 indexed citations
5.
O’Shaughnessy, Joyce, Angela DeMichele, X. Cynthia, et al.. (2018). A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Research and Treatment. 170(3). 547–557. 35 indexed citations
6.
7.
Frappaz, Didier, Sara M. Federico, Andrew D.J. Pearson, et al.. (2016). Phase 1 study of dalotuzumab monotherapy and ridaforolimus–dalotuzumab combination therapy in paediatric patients with advanced solid tumours. European Journal of Cancer. 62. 9–17. 21 indexed citations
8.
Pearson, Andrew D.J., Sara M. Federico, Isabelle Aerts, et al.. (2016). A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. Oncotarget. 7(51). 84736–84747. 22 indexed citations
9.
Garcia‐Manero, Guillermo, Giovanni Martinelli, Joshua F. Zeidner, et al.. (2014). A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.. Journal of Clinical Oncology. 32(15_suppl). TPS3116–TPS3116. 3 indexed citations
10.
Pearson, Andrew D.J., Sara M. Federico, Isabelle Aerts, et al.. (2013). A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 10027–10027. 2 indexed citations
11.
Frappaz, Didier, Lisa M. McGregor, Andrew D.J. Pearson, et al.. (2013). A phase I study of the anti-insulin like growth factor type 1 receptor (IGF-1R) antibody dalotuzumab in pediatric patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 10026–10026. 1 indexed citations
12.
Geschwindt, Ryan, Curtis L. Glover, Lý Thị Trần, et al.. (2007). MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma. Clinical Chemistry. 53(4). 666–672. 110 indexed citations
13.
14.
DeScipio, Cheryl, Lori Schneider, Terri L. Young, et al.. (2005). Subtelomeric deletions of chromosome 6p: Molecular and cytogenetic characterization of three new cases with phenotypic overlap with Ritscher?Schinzel (3C) syndrome. American Journal of Medical Genetics Part A. 134A(1). 3–11. 54 indexed citations
15.
Lu, Xuanyong, et al.. (2001). Hepatitis B Virus MHBs Antigen Is Selectively Sensitive to Glucosidase-Mediated Processing in the Endoplasmic Reticulum. DNA and Cell Biology. 20(10). 647–656. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wan Sun Breakdown of academic impact, for papers by Kevin Huang Breakdown of academic impact, for papers by Sarah Benafif Breakdown of academic impact, for papers by Karan Rai Breakdown of academic impact, for papers by Hualei Bu Breakdown of academic impact, for papers by Siân Morgan Breakdown of academic impact, for papers by Valentina Sini Breakdown of academic impact, for papers by C. K. Park Breakdown of academic impact, for papers by Nicoletta Provinciali
Rankless by CCL
2026